Aim:To assess the Feto-Maternal Outcome in Covid-19 Positive Pregnancies Study design: A retrospective study Place and duration: This study was conducted at Sheikh khalifa bin Zayed hospital Quetta, Pakistan from February 2020 to Feburary2021 Methodology:After ethical committee approval for the study, all medical records were evaluated for symptomatic and asymptomatic COVID-19 positive pregnant females. After admission to the hospital, an experienced healthcare worker validated the SARS-COV-2 status of all afflicted women by taking nasopharyngeal swabs for real-time RT-PCR following WHO criteria.Bothfeto-maternal outcomes were observed, including psychological stress, fever, cough, sore throat, dyspnea, ICU hospitalizations, pneumonia, maternal transfer of COVID to newborn. SPSS version 22 was used to analyze the data. Results:The present study investigated 72 COVID-19 positive pregnant women. The mean age of females was 28 ± 5.6 years, and the mean gestational age was 37 weeks. The common symptoms were anxiety (18.1%), runny nose with fever (12.5%), cough and fever (9.7%), and sore throat (8.3), whereas 48.6% of cases were asymptomatic. Co-Morbidities include Hypertension (19.7), Anemia (8.3%), Diabetes Mellitus (5.6%), and Hypothyroidism (2.8%). Conclusion: The clinical course of COVID-19 infection in pregnant women appears similar to that of non-pregnant women. There was no vertical transmission of COVID-19, nor was there any neonatal mortality. Keywords: COVID-19, feto-maternal transmission, pandemic, pregnancy outcome
Introduction: Abnormal uterine bleeding (AUB) can occur at any age in a woman’s life, and it is more prevalent in the premenopausal age group. Although anovulation is the most prevalent endometrial cause, other major reasons include endometrial hyperplasia, endometrial adenomatous polyps and cancer. For patients of all ages, it is one of the most prevalent presentations in Gynecology OPDs. AUB has a major impact on health-related quality of life, necessitating quick intervention. AUB treatment is difficult without a good diagnosis. As a result, pre-menopausal and post-menopausal women with AUB must have a thorough examination to rule out endometrial cancer. Aim: To assess the role of transvaginal ultrasound and color Doppler tomography (CDTU) in irregular uterine bleeding and correlate these findings with histological diagnosis. Methodology: The present study included 92 individuals with abnormal uterine bleeding (AUB), in those TVS, and Color Doppler was used to evaluate the endometrial pathologies. Endometrium, uterine size and any uterine or adnexal disease were evaluated during the TVS. Spiral arteries of the endometrium and uterine arteries were studied for their vascular patterns. The RI and PI of the uterine artery were determined. For PI, a cutoff of 1.83 was used, while for RI, a cutoff of 0.81 was used. The results were then compared to endometrial histology. Results: According to TVS, (see Table 1) the most common causes of AUB were leiomyoma (15.2%), polyp (12%), PCOS (9.8%), adenomyosis (5.43%) and endometrial development (3.3%). The uterine indicators of RI (0.81) and PI (1.83) of the uterine artery by CDTU revealed 11 patients with probable cancer. For AUB M, the TVS with CDTU specificity and sensitivity was 100 percent and 90.77 percent, respectively. The positive predictive value was 45%, whereas the negative predictive value was 100%. Conclusion: The use of vascular impedance and color Doppler of the uterine artery and endometrial spiral arteries improves the diagnostic accuracy of TVS for the prediction of endometrial diseases. It makes screening for malignant and premalignant lesions easier.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.